2 Information about solriamfetol
Marketing authorisation indication
2.1 Solriamfetol (Sunosi, Jazz Pharmaceuticals) has a marketing authorisation 'to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy)'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.